Brainstorm Cell Therapeutics (BCLI) Tops Q2 EPS by 3c

Brainstorm Cell Therapeutics (NASDAQ: BCLI) reported Q2 EPS of ($0.04), $0.03 better than the analyst estimate of ($0.07).

For earnings history and earnings-related data on Brainstorm Cell Therapeutics (BCLI) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Winnebago Industries (WGO) PT Lowered to $40 at Benchmark on Pressured NT Demand
• Abbvie (ABBV) PT Raised to $273 at Canaccord